TTC21A, also known as tetratricopeptide repeat domain 21A, is a protein that has not been as extensively characterized as some other proteins. However, based on its name and the presence of the tetratricopeptide repeat (TPR) domain, it can be inferred that it likely plays a role in protein-protein interactions and may be involved in the assembly of multiprotein complexes.The TPR motif is a structural motif present in a variety of proteins and is known to facilitate protein-protein interactions. It consists of a series of tandem repeats of 34 amino acids that form a helix-turn-helix structure. This structure often acts as a scaffold for the formation of protein complexes, which are essential for various cellular processes, such as signal transduction, protein folding, and transport.
Proteins containing TPR domains are involved in a wide range of functions. For example, they can mediate the interaction between chaperone proteins such as Hsp70/Hsp90 and their co-chaperones, which are crucial for protein folding and stabilization. TPR domain proteins are also found in the mitochondrial import machinery, where they recognize mitochondrial targeting sequences and facilitate the import of proteins into the mitochondria. Research into TTC21A and other less-characterized proteins is important for expanding our understanding of cellular function and may lead to the identification of novel pathways.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
Proteasome inhibitor, could indirectly affect TTC21A by altering protein degradation pathways and affecting protein stability. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Another proteasome inhibitor, potentially influencing TTC21A by modulating proteasomal degradation of proteins. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $40.00 $82.00 $256.00 | 127 | |
Inhibits protein synthesis, could indirectly affect TTC21A by altering the overall protein synthesis and degradation balance. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
mTOR inhibitor, potentially affecting TTC21A by modulating cellular growth and protein synthesis pathways. | ||||||
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
Glycogen synthase kinase-3 (GSK-3) inhibitor, potentially influencing TTC21A through Wnt/β-catenin signaling pathways. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $80.00 $212.00 $408.00 | 48 | |
TGF-β receptor inhibitor, might indirectly affect TTC21A by altering TGF-β signaling pathways involved in protein regulation and cell signaling. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
PI3K inhibitor, potentially affecting TTC21A activity by modulating the PI3K/Akt signaling pathway, which is involved in various cellular processes including protein regulation. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
MEK inhibitor, potentially affecting TTC21A by modulating the MAPK/ERK signaling pathway. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Another PI3K inhibitor, could indirectly influence TTC21A activity through the PI3K/Akt pathway. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Histone deacetylase inhibitor, can affect gene expression and protein interactions, potentially impacting TTC21A. | ||||||